The spectrum of Vogt-Koyanagi-Harada disease in Turkey

Tuğal-Tutkun, İlknur; Özyazgan, Yılmaz; Akova, Yonca A.; Süllü, Yüksel; Akyol, Nurettin; Soylu, Merih; Kazokoğlu, Haluk

doi:10.1007/s10792-006-9001-1

Cited by 54 publications

(28 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings without a doubt provide the answer for the unexplained high proportion of VKH cases that progress towards sunset glow fundus despite the fact that the disease seemed to be clinically quiet. Indeed, the very high frequency of sunset glow fundus reported from all over the world reaches proportions as high as 89% in Turkey [20], 93% in Japanese patients with chronic inflammation [21] and 95.8% in China [22]. Many authors have tried to find an explanation for the irremediable progression of disease towards sunset glow fundus even in the absence of manifest clinical disease, and some have correlated sunset glow fundus with central nervous system involvement or inflammatory disease activity [21,23] However, it would be more sensible to correlate sunset glow fundus with choroidal inflammatory disease activity and link it directly to this factor.…”

Section: Discussionmentioning

confidence: 99%

Indocyanine green angiography in Vogt–Koyanagi–Harada disease: angiographic signs and utility in patient follow-up

2007

View full text Add to dashboard Cite

Choroidal inflammation shown by ICG angiography can be suppressed completely by initial high-dose inflammation suppressive therapy. However, recurrent subclinical choroidal inflammation is detected at the end of the tapering period in a high proportion of cases. This indicates that, in the absence of an ICGA follow-up, undetected smoldering subclinical disease may persist, thereby explaining the frequently reported evolution towards sunset glow fundus despite an apparently controlled disease. This is a clear indication that VKH disease should be followed by ICG angiography and, in the case of choroidal subclinical reactivation, a reversal of therapy tapering and an extension of therapy duration should be considered.

show abstract

Section: Discussionmentioning

confidence: 99%

Indocyanine green angiography in Vogt–Koyanagi–Harada disease: angiographic signs and utility in patient follow-up

2007

View full text Add to dashboard Cite

show abstract

“…7 Somewhat ironically, recent clinic-based studies have suggested that half or more of all patients with ocular findings consistent with acute disease have uveitis alone, or probable VKH. [8][9][10][11][12] Rao et al studied the frequency of distinguishing clinical features of VKH disease observed in patients with bilateral uveitis who presented over a 3-month period at 10 uveitis centers in the United States, Europe, Northern Africa, India and Asia. 13 Although a number of symptoms and signs were relatively more common in patients with VKH disease as compared to those with non-VKH uveitis, the findings most predictive of VKH disease were exudative retinal detachment during the acute uveitic phase (likelihood ratio 41.8; 95% CI 5.9-295.1) and choroidal depigmentation, or ''sunset glow fundus,'' during the chronic/recurrent phase of the disease (likelihood ratio 50.2; 95% CI 22.6-111.3).…”

mentioning

confidence: 99%

“…These findings were generally consistent with reports of other clinic-based cohorts, including an unrelated cohort from Turkey. 9 Xu et al examined either serum interleukin (IL)-25 levels or the effect of a physiologic concentration of IL-25 on lipopolysaccharide (LPS)-induced IL-1b, IL-6, and TNF-a release from peripheral blood mononuclear cells (PBMC) in separate subsets of 22 patients with active VKH disease, including 15 patients in the acute uveitic phase and seven with chronic/recurrent inflammation. 24 Twelve of the patients with VKH disease were seen prior to treatment, whereas 10 were treated with low dose systemic prednisone within 2 months of testing.…”

mentioning

confidence: 99%

Vogt-Koyanagi-Harada Disease

Cunningham

Rathinam

Tuğal-Tutkun

et al. 2014

Ocular Immunology and Inflammation

Self Cite

View full text Add to dashboard Cite

“…Hastal›¤›n önemli bir bulgusu göz tutulumu olup, s›kl›kla kronik ve iki tarafl› panüveit tarz›nda klini¤e yans›maktad›r. VKH tan›s› için önemli olan husus di¤er üveit nedenlerinin ekarte edilmesi ve yard›mc› klinik bulgular›n do¤ru bir biçimde yorumlan-mas›d›r (4,5).…”

Section: Giriflunclassified

Clinical Features of Cases of Vogt-Koyanagi-Harada Syndrome

Ceylan¹,

Uysal²,

Türk³

et al. 2010

tjo

View full text Add to dashboard Cite

ÖzetAmaç: Vogt-Koyanagi-Harada (VKH) hastal›¤›na sahip olgular›m›z›n klinik özelliklerini sunmak. Gereç ve Yöntem:Ocak 2001-Ocak 2010 tarihleri aras›nda klini¤imize baflvuran toplam 10 VKH olgusuna ait t›bbi kay›tlar geriye dönük olarak incelendi. Sonuçlar:On erkek hastan›n ortalama yafl› 21.9 y›l idi. Ortalama takip süresi 16,2 ayd›. Yedi olguda iki tarafl› tutulum, üç olguda tek tarafl› tutulum mevcuttu. Toplam 17 gözün bafllang›ç görme keskinli¤i de¤erleri ortalama olarak 0,51 idi. Ondört gözde ön üveit, 12 gözde vitritis mevcuttu. Optik disk hiperemisi 16 gözde bulunmaktayd›. Oniki gözün eksüdatif retina dekolman› ve befl gözün hafif retinal depigmentasyon alanlar› mevcuttu. Tüm olgular fundus floresein anjiografisi ve ultrasonografi ile de¤erlendirilmiflti. ‹flitsel flikâyetler iki olguda görüldü. ‹lk muayene sürecinde alt› olgunun beyin omurilik s›v›s›nda pleositoz tespit edildi. Dört olguda cilt bulgular› görüldü. Tüm olgular yüksek doz oral kortikosteroid tedavisi ile tedavi edildi. Üç olguda ilave olarak siklosporin tedavisi eklendi. Sonuç görme düzeyi ortalama olarak 0,86 idi. Tart›flma: VKH hastal›¤›nda, özellikle erken dönemde baflvuran vakalarda görme prognozu genellikle iyi olmaktad›r. Görme düzeyini artt›rmada kortikosteroidlerle yap›lan tedavi oldukça etkili olup, kortikosteroid tedavisine dirençli olgularda immünsüpresif ilaçlar gerekli olabilir. (TJO 2010; 40: 250-4) Anahtar Kelimeler: Tedavi sonucu, uveit, Vogt-Koyanagi-Harada hastal›¤› Summary Purpose: To report the clinical features of our cases of Vogt-Koyanagi-Harada (VKH) disease. Material and Method: Medical records of totally 10 VKH patients whoResults: The mean age of 10 male patients was 21.9 years. The mean follow-up period was 16.2 months. Seven cases had bilateral involvement and three had unilateral. The mean initial visual acuity was 0.51 in a total of 17 eyes. Fourteen eyes had anterior uveitis and twelve eyes had vitritis. Optic disc hyperemia was present in sixteen eyes. Twelve eyes had exudative retinal detachment and five eyes had areas of slight retinal depigmentation. All cases were evaluated with fundus fluorescein angiography and ultrasonography. Auditory disturbances were seen in two cases. On first examination, pleocytosis was detected in the cerebrospinal fluid samples from six patients. Integumentary findings were seen in four cases. All subjects were treated with high-dose oral corticosteriod, but three of them additionally received cyclosporine therapy. The mean final visual acuity was 0.86. Discussion:In VKH disease, visual prognosis is generally good, especially in cases presenting in the early period. Treatment with corticosteroids is quite effective in improving the visual acuity, and immunosuppressive drugs may be needed in cases of corticosteroid resistance. (TJO 2010; 40: 250-4)

show abstract

The spectrum of Vogt-Koyanagi-Harada disease in Turkey

Abstract: VKH disease is rare in Turkey. We conclude that the majority of patients with VKH in Turkey do not have the complete form of the disease. Based on our results, most patients with VKH seem to be late referrals. Ocular complications were common among these patients.

Cited by 54 publications

References 15 publications

Indocyanine green angiography in Vogt–Koyanagi–Harada disease: angiographic signs and utility in patient follow-up

Indocyanine green angiography in Vogt–Koyanagi–Harada disease: angiographic signs and utility in patient follow-up

Vogt-Koyanagi-Harada Disease

Clinical Features of Cases of Vogt-Koyanagi-Harada Syndrome

Contact Info

Product

Resources

About